Dr. Voliotis has joined Convergent as of September 2023. He is a Board-certified Medical Oncologist & Hematologist with an international background of over 18 years of successful pharmaceutical industry experience (US and Europe) in global development leadership positions at Bayer Healthcare and Eisai Pharmaceuticals. Dr. Voliotis has been involved in the development of over 40 compounds, including small molecule targeted therapeutics, monoclonal antibodies, chemotherapeutics and immunoconjugates. He has been responsible for multiple drugs that have achieved approval, including the radiopharmaceutical Xofigo® in prostate cancer, as well as for Nexavar®, Halaven® and Lenvima®, in different indications. Prior to Convergent, Dimitris was the Global Head of Clinical Development at Zentalis Pharmaceuticals. At Zentalis, he was responsible for leading four INDs, associated clinical studies in solid tumor oncology and hematology-oncology indications, as well as the coordination of clinical pipeline projects.